Cargando…
A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963271/ https://www.ncbi.nlm.nih.gov/pubmed/31810359 http://dx.doi.org/10.3390/pathogens8040281 |
_version_ | 1783488242696323072 |
---|---|
author | Shehata, Mahmoud M. Kandeil, Ahmed Mostafa, Ahmed Mahmoud, Sara H. Gomaa, Mokhtar R. El-Shesheny, Rabeh Webby, Richard Kayali, Ghazi A. Ali, Mohamed |
author_facet | Shehata, Mahmoud M. Kandeil, Ahmed Mostafa, Ahmed Mahmoud, Sara H. Gomaa, Mokhtar R. El-Shesheny, Rabeh Webby, Richard Kayali, Ghazi A. Ali, Mohamed |
author_sort | Shehata, Mahmoud M. |
collection | PubMed |
description | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses. |
format | Online Article Text |
id | pubmed-6963271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69632712020-02-26 A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice Shehata, Mahmoud M. Kandeil, Ahmed Mostafa, Ahmed Mahmoud, Sara H. Gomaa, Mokhtar R. El-Shesheny, Rabeh Webby, Richard Kayali, Ghazi A. Ali, Mohamed Pathogens Article Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses. MDPI 2019-12-02 /pmc/articles/PMC6963271/ /pubmed/31810359 http://dx.doi.org/10.3390/pathogens8040281 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shehata, Mahmoud M. Kandeil, Ahmed Mostafa, Ahmed Mahmoud, Sara H. Gomaa, Mokhtar R. El-Shesheny, Rabeh Webby, Richard Kayali, Ghazi A. Ali, Mohamed A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title | A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title_full | A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title_fullStr | A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title_full_unstemmed | A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title_short | A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice |
title_sort | recombinant influenza a/h1n1 carrying a short immunogenic peptide of mers-cov as bivalent vaccine in balb/c mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963271/ https://www.ncbi.nlm.nih.gov/pubmed/31810359 http://dx.doi.org/10.3390/pathogens8040281 |
work_keys_str_mv | AT shehatamahmoudm arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT kandeilahmed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT mostafaahmed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT mahmoudsarah arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT gomaamokhtarr arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT elsheshenyrabeh arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT webbyrichard arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT kayalighazi arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT aalimohamed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT shehatamahmoudm recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT kandeilahmed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT mostafaahmed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT mahmoudsarah recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT gomaamokhtarr recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT elsheshenyrabeh recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT webbyrichard recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT kayalighazi recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice AT aalimohamed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice |